KROS:NASDAQ
Keros Therapeutics Inc
$ą„Æ.ą„©ą„¬
arrow_downward
-ą„¦.ą„Æą„«%(-ą„¦.ą„¦ą„Æą„¦) ą„§ दि
$ą„Æ.ą„©ą„¬
ą„¦.ą„¦ą„¦% (ą„¦.ą„¦ą„¦)
bedtimeą¤®ą¤¾ą¤°ą„ą¤ą„ą¤ą¤ą„या ą¤µą„ą¤³ą„ą¤Øą¤ą¤¤ą¤°
ą¤¬ą¤ą¤¦: ą„¬ ą¤Øą„ą¤µą„ą¤¹ą„ą¤, ą„Ŗ:ą„¦ą„¦:ą„¦ą„§ PM [GMT]-ą„« · USD
search
ą¤øą¤°ą„ą¤µ ą¤øą¤æą¤®ą„ą¤¬ą„ल
| ą¤øą¤æą¤®ą„ą¤¬ą„ल | ą¤ą¤æą¤ą¤®ą¤¤ | बदल | % बदल |
|---|
insights_autoKROS ą¤øą¤¾ą¤ ą„ ą¤ą„प ą¤ą¤Øą¤øą¤¾ą¤ą¤ ą¤ą¤Øą¤°ą„ą¤ ą¤ą¤°ą¤¤ ą¤ą¤¹ą„...
ą¤ą¤ą¤”ा
$ą„Æ.ą„ą„Ŗ
ą¤ą¤ą„ą¤
$ą„Æ.ą„Æą„®
ą¤ą¤®ą„
$ą„Æ.ą„Øą„¬
ą¤®ą¤¾ą¤°ą„ą¤ą„ą¤ ą¤ą„
प
ą„§ą„®.ą„«ą„¬Ā ą¤ą„ą¤ą„
ą¤øą¤°ą¤¾ą¤øą¤°ą„ ą¤ą¤²ą¤¾ą¤¢ą¤¾ą¤²
ą„§.ą„¬ą„«Ā ą¤²ą¤¾ą¤
ą¤ą¤²ą¤¾ą¤¢ą¤¾ą¤²
ą„§.ą„Æą„ØĀ ą¤²ą¤¾ą¤
ą„«ą„Ø ą¤ą¤ ą¤µą¤”ą„ą¤Æą¤¾ą¤ą¤¤ą„ल ą¤ą¤ą„ą¤ą¤¾ą¤ą¤
$ą„Øą„Ø.ą„«ą„«
ą„«ą„Ø ą¤ą¤ ą¤µą¤”ą„ą¤Æą¤¾ą¤ą¤¤ą„ल ą¤Øą„ą¤ą¤¾ą¤ą¤
$ą„Æ.ą„Øą„¬
EPS
-$ą„©.ą„ą„¦
ą¤¬ą„ą¤ą¤¾
ą„§.ą„§ą„©
ą¤„ą¤ą¤æą¤¤ ą¤¶ą„ą¤
र
ą„§.ą„Æą„®Ā ą¤ą„ą¤ą„
ą¤ą¤°ą„ą¤®ą¤ą¤¾ą¤±ą„ą¤Æą¤¾ą¤ą¤ą„ ą¤øą¤ą¤ą„या
ą„Æą„Ø
ą¤ą¤ą¤”ा
$ą„Æ.ą„ą„Ŗ
ą¤ą¤ą„ą¤
$ą„Æ.ą„Æą„®
ą¤ą¤®ą„
$ą„Æ.ą„Øą„¬
ą¤®ą¤¾ą¤°ą„ą¤ą„ą¤ ą¤ą„
प
ą„§ą„®.ą„«ą„¬Ā ą¤ą„ą¤ą„
ą¤øą¤°ą¤¾ą¤øą¤°ą„ ą¤ą¤²ą¤¾ą¤¢ą¤¾ą¤²
ą„§.ą„¬ą„«Ā ą¤²ą¤¾ą¤
ą¤ą¤²ą¤¾ą¤¢ą¤¾ą¤²
ą„§.ą„Æą„ØĀ ą¤²ą¤¾ą¤
ą„«ą„Ø ą¤ą¤ ą¤µą¤”ą„ą¤Æą¤¾ą¤ą¤¤ą„ल ą¤ą¤ą„ą¤ą¤¾ą¤ą¤
$ą„Øą„Ø.ą„«ą„«
ą„«ą„Ø ą¤ą¤ ą¤µą¤”ą„ą¤Æą¤¾ą¤ą¤¤ą„ल ą¤Øą„ą¤ą¤¾ą¤ą¤
$ą„Æ.ą„Øą„¬
EPS
-$ą„©.ą„ą„¦
ą¤¬ą„ą¤ą¤¾
ą„§.ą„§ą„©
ą¤„ą¤ą¤æą¤¤ ą¤¶ą„ą¤
र
ą„§.ą„Æą„®Ā ą¤ą„ą¤ą„
ą¤ą¤°ą„ą¤®ą¤ą¤¾ą¤±ą„ą¤Æą¤¾ą¤ą¤ą„ ą¤øą¤ą¤ą„या
ą„Æą„Ø
ą¤¬ą¤¾ą¤¤ą¤®ą„ą¤Æą¤¾ą¤ą¤ą„या ą¤øą„ą¤ą„रą„
ą¤µą„ą¤¬ ą¤øą„ą¤°ą„त ą¤ą¤£ą¤æ ą¤¬ą¤¾ą¤¤ą¤®ą„ ą¤ą¤¾ą¤ą„ą¤¦ą¤¾ą¤°ą¤¾ą¤ą¤ą¤”ą„ą¤Ø
Investing.com
·
ą„Ø ą¤¦ą¤æą¤µą¤øą¤¾ą¤ą¤Ŗą„ą¤°ą„ą¤µą„
Keros earnings beat by $1.64, revenue topped estimates
Yahoo Finance
·
ą„Ø ą¤¦ą¤æą¤µą¤øą¤¾ą¤ą¤Ŗą„ą¤°ą„ą¤µą„
Keros Therapeutics, Inc. (KROS) Q3 Earnings and Revenues Surpass Estimates
Keros Therapeutics Inc ą¤¬ą¤¦ą„ą¤¦ą¤²
CEO-
ą¤ą¤°ą„ą¤®ą¤ą¤¾ą¤°ą„ą„Æą„Ø
ą¤øą„ą¤„ą¤¾ą¤Ŗą¤Øą¤¾ą„Øą„¦ą„§ą„«
ą¤®ą„ą¤ą„यालयą„Lexington, मą„
ą¤øą„ą¤ą„ą¤Æą„ą¤øą„ą¤ą„स, ą¤øą¤ą¤Æą„ą¤ą„त ą¤°ą¤¾ą¤·ą„ą¤ą„र
ą¤ą„ą¤·ą„ą¤¤ą„रHealth Care
ą¤ą¤¦ą„ą¤Æą„ą¤-
ą¤µą„ą¤¬ą¤øą¤¾ą¤ą¤kerostx.com